Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick – President and Chief Executive Officer Andrew Sims – Vice President and Chief Financial Officer Norman LaFrance – Chief Medical Officer Conference Call Participants Justin Walsh – Jones Trading Sean Lee – H.C. Wainwright Edward Woo…

Read More

PROS Holdings, Inc. (PRO) Q3 2023 Earnings Call Transcript

PROS Holdings, Inc. (NYSE:PRO) Q3 2023 Earnings Conference Call October 31, 2023 4:45 PM ET Company Participants Belinda Overdeput – Director, IR Andres Reiner – President & CEO Stefan Schulz – CFO Conference Call Participants Chad Bennett – Craig-Hallum Capital Group Rob Oliver – Baird Jason Celino – KeyBanc Capital Markets Scott Berg – Needham…

Read More

Ferrovial, S.A. (FRRVF) Q3 2023 Earnings Call Transcript

Ferrovial, S.A. (OTCPK:FRRVF) Q3 2023 Earnings Conference Call October 31, 2023 1:00 PM ET Company Participants Silvia Ruiz – Head-Investor Relations Ernesto López Mozo – Chief Financial Officer Jose Velao – Chief Financial Officer-Cintra Iñaki Garcia-Bilbao – Chief Financial Officer-Ferrovial Construction Laura López – Chief Financial Officer-Ferrovial Airports Conference Call Participants Silvia Ruiz Good afternoon…

Read More

CVR Partners, LP (UAN) Q3 2023 Earnings Call Transcript

CVR Partners, LP (NYSE:UAN) Q3 2023 Earnings Conference Call October 31, 2023 11:00 AM ET Company Participants Richard Roberts – Director, Financial Planning and Analysis and IR Mark Pytosh – CEO Dane Neumann – CFO Conference Call Participants Rob McGuire – Granite Research Operator Greetings, and welcome to the CVR Partners LP Third Quarter 2023…

Read More

Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity (CPRX)

koto_feja/E+ via Getty Images Company website Investment Thesis Rating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Buy with 2-5 year target of $40 (3x upside) based on the discounted cash flow (“DCF”) valuation method. Steroids are used in 70% of patients with Duchenne’s muscular dystrophy, DMD, a debilitating neuromuscular disease, which is a 2 billion/year market and is…

Read More

VO: Better Valuations, Bullish Seasonals

Nikada Nearly all stocks outside of the US megacap Magnificent Seven have produced negative alpha this year. Stretch out the performance scope to five years, and you’ll also see heavy underperformance among value stocks, foreign equities, and domestic SMID caps. But did you know: It’s not big glamour stocks, strength overseas, or US small-caps that…

Read More